Thyroiditis

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

Retrieved on: 
Tuesday, April 12, 2022
Health, General Health, Psoriatic arthritis, Inflammation, Ageing, Inflammatory bowel disease, Joint, Comparison, Macrophage, Sarcopenia, Disease, Investigational New Drug, Lymphocyte, Multiple sclerosis, RA, IND, COVID-19, TNF, Cannabidiol, Intention, Annual report, Saudi Research and Marketing Group, Bacteria, Human, Traffic barrier, CNS, Central nervous system, Drug discovery, Brain, Warfarin necrosis, Autoimmune disease, Arthritis, Data, Rheumatoid arthritis, Nasdaq, Immune system, Company, Bone erosion, Chronic pain, Thyroiditis, Frailty, Forward-looking statement, IL-6, Degenerative disease, Animal, Research, Diabetes, FDA, Genta (company), Multimedia, MS, Epilepsy, Ease, Cytokine, Longevity, Pharmaceutical industry, Frankincense, CBD, Etanercept

Rheumatoid arthritis is a chronic autoimmune disease and an inflammatory form of arthritis.

Key Points: 
  • Rheumatoid arthritis is a chronic autoimmune disease and an inflammatory form of arthritis.
  • Rheumatoid arthritis is the most common form of autoimmune arthritis, affecting more than 1.3 million Americans4 and occuring at any age.
  • Studies have determined that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 20405.
  • Moreover, microscopic changes associated with rheumatoid arthritis (e.g., inflammation, bone erosion, and bone degeneration) are observed in CAIA control animals.

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Retrieved on: 
Tuesday, April 5, 2022
Health, General Health, Acumen, Autoimmunity, Company, Genta (company), Multiple sclerosis, Human, Inflammation, Degenerative disease, Traffic barrier, Forward-looking statement, Frailty, Pharmacokinetics, Longevity, Thyroiditis, Central nervous system, Cannabidiol, CNS, Ageing, Sarcopenia, Immune system, TNF, Chronic pain, Intention, MS, Nasdaq, COVID-19, Life expectancy, Epilepsy, Warfarin necrosis, Acceleration, Annual report, FDA, Patient, Disease, Pharmaceutical industry, CBD

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced an acceleration in the pace of new patient dosing in the Companys fully funded Phase 2 clinical trial of lead drug candidate MYMD-1 as a therapy for delaying aging and expanding healthy lifespan.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced an acceleration in the pace of new patient dosing in the Companys fully funded Phase 2 clinical trial of lead drug candidate MYMD-1 as a therapy for delaying aging and expanding healthy lifespan.
  • Chronic inflammation is a common factor in aging and all aging-related diseases including frailty, sarcopenia (loss of muscle tissue), and autoimmunity.
  • Originally developed for autoimmune diseases, MYMD-1s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms.

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Retrieved on: 
Wednesday, February 23, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Acumen, Central nervous system, Thyroiditis, Chronic pain, Human, Population, Degenerative disease, Sarcopenia, Compte rendu, Diabetes, Pharmacokinetics, Inflammation, Prevalence, Toxicity, Immune system, COVID-19, Cannabidiol, Inflammatory bowel disease, Life expectancy, Safety, Disease, RA, IL-6, Multiple sclerosis, Traffic barrier, Epilepsy, MS, Protein, Rheumatoid arthritis, Intention, Warfarin necrosis, FDA, Autoimmune disease, Blood, Nasdaq, TNF, Forward-looking statement, Ageing, Patient, Â, Frailty, CNS, Longevity, Pharmaceutical industry, CBD, MYMD-1, MyMD Pharmaceuticals, Inc., MYMD-1, MYMD PHARMACEUTICALS, INC.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that the first patient has been enrolled in the Companys Phase 2 clinical trial of lead candidate MYMD-1, an oral immune regulator drug, as a therapy for delaying aging and expanding healthy lifespan.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that the first patient has been enrolled in the Companys Phase 2 clinical trial of lead candidate MYMD-1, an oral immune regulator drug, as a therapy for delaying aging and expanding healthy lifespan.
  • In a Phase 1 clinical trial of MYMD-1, we demonstrated the drugs statistically significant efficacy in reducing levels of TNF-, a key player in causing pathological aging, in the blood.
  • The initiation of patient enrollment in this study advances our mission to slow the aging process, prevent loss of muscle tissue in aging, limit frailty, and extend healthy lifespan.
  • Originally developed for autoimmune diseases, MYMD-1s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

Retrieved on: 
Wednesday, December 1, 2021
Biotechnology, Alternative Medicine, Health, Pharmaceutical, Clinical Trials, Sarcopenia, Ageing, Anxiety, Degenerative disease, Inflammation, Brain, Forward-looking statement, Frailty, Company, MS, Multiple sclerosis, Traffic barrier, Central nervous system, Warfarin necrosis, Longevity, COVID-19, Pain, CB1, Chronic pain, Nasdaq, Cannabidiol, FDA, Thyroiditis, Compte rendu, Intention, Immune system, Epilepsy, Neurodegeneration, CNS, Disease, TNF, CB2, Pharmaceutical industry

During the conferences, MyMD executives will discuss the multiple indications being pursued and market opportunities for novel drug candidates MYMD-1 and Supera-CBD.

Key Points: 
  • During the conferences, MyMD executives will discuss the multiple indications being pursued and market opportunities for novel drug candidates MYMD-1 and Supera-CBD.
  • Originally developed for autoimmune diseases, MYMD-1s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.
  • MYMD-1 is also showing promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.
  • A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed by MyMD on November 12, 2021 (as amended on November 15, 2021).

MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan

Retrieved on: 
Tuesday, November 23, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Sarcopenia, Patent, Ageing, Degenerative disease, Disorder, Inflammation, Diabetes, Forward-looking statement, USPTO, Frailty, Asthma, MS, Multiple sclerosis, Rheumatoid arthritis, Traffic barrier, Central nervous system, Warfarin necrosis, Longevity, COVID-19, Chronic pain, Nasdaq, Cannabidiol, FDA, Thyroiditis, Compte rendu, Intention, Immune system, Fibrosis, Epilepsy, Method, CNS, Disease, TNF, IP, Pharmaceutical industry

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled Methods of Reversing Normal Aging Process and Extending Lifespan.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled Methods of Reversing Normal Aging Process and Extending Lifespan.
  • The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual.
  • Our primary focus for MYMD-1 is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan, Dr. Chapman added.
  • Originally developed for autoimmune diseases, MYMD-1s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Retrieved on: 
Tuesday, November 16, 2021
FDA, Men, Health, Consumer, Other Health, Pharmaceutical, Other Science, Research, General Health, Other Consumer, Science, Women, Seniors, Clinical Trials, Acumen, Traffic barrier, Population, Safety, Sarcopenia, Autoimmunity, Epilepsy, Muscle, Food and Drug Administration, Compte rendu, Multiple sclerosis, Immune system, Disease, Life expectancy, Longevity, Food, Inflammation, Chronic pain, COVID-19, Frailty, Forward-looking statement, FDA, Intention, CNS, Protein, Systemic inflammation, IL-6, Cannabidiol, Degenerative disease, Thyroiditis, Pharmacokinetics, Toxicity, TNF, Warfarin necrosis, Central nervous system, Nasdaq, Patient, Life, MS, Ageing, IND, Pharmaceutical industry, MYMD-1, MyMD Pharmaceuticals, Inc., MYMD-1, MYMD PHARMACEUTICALS, INC.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan.
  • Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022.
  • To our knowledge, ours is the only IND application ever accepted by the FDA for a Phase 2 trial of a patented drug that seeks to delay aging.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms.

EMD Serono to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021

Retrieved on: 
Sunday, September 12, 2021
Managed Care, Research, Radiology, Pharmaceutical, Oncology, Hospitals, Clinical Trials, Science, Biotechnology, Nursing, FDA, Health, Other Science, BAVENCIO® (avelumab), Tepotinib, Berzosertib, Bintrafusp Alfa, EMD Serono, Inc., Merck KGaA, Darmstadt, Germany, BAVENCIO® (AVELUMAB), TEPOTINIB, BERZOSERTIB, BINTRAFUSP ALFA, EMD SERONO, INC., MERCK KGAA, DARMSTADT, GERMANY

EMD Serono is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer.

Key Points: 
  • EMD Serono is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer.
  • Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month.
  • Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
  • The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.

Thyroid Awareness Month: Fed Up with Toxic Skincare, Mom with Thyroid Autoimmune Disease Launches Own Brand

Retrieved on: 
Tuesday, January 14, 2020
Thyroid disease, Medical specialties, Medicine, Organ systems, Thyroiditis, Hashimoto's thyroiditis, Autoimmunity, Thyroid, Autoimmune disease, Autoantibody, Autoimmune thyroiditis

The persistent brain fog, achy joints, and chronic fatigue weren't the realities of her busy days as a single Mom and entrepreneur.

Key Points: 
  • The persistent brain fog, achy joints, and chronic fatigue weren't the realities of her busy days as a single Mom and entrepreneur.
  • They were the symptoms of Hashimoto's Thyroiditis, an autoimmune disease affecting more than 14 million people.
  • This in turn wreaks havoc on overall health and is a common trigger for autoimmune disease.
  • I want other Hashimoto's and autoimmune disease sufferers to know they have options when it comes to skin care.

Triad Of Health Family Healing Center Reveals The Seven Pitfalls You Must Avoid To Heal Your Thyroid

Retrieved on: 
Monday, June 18, 2018
Thyroid disease, Anatomy, RTT, Medicine, Autoimmune diseases, Thyroid, Thyroiditis, Hashimoto's thyroiditis, Autoimmunity, Graves' disease

In the conventional medical model, the main therapies available for Hashimoto's Thyroiditis and Grave's Disease are prescription or other medications, surgical removal of the thyroid, and possibly radiation therapy or a combination thereof.

Key Points: 
  • In the conventional medical model, the main therapies available for Hashimoto's Thyroiditis and Grave's Disease are prescription or other medications, surgical removal of the thyroid, and possibly radiation therapy or a combination thereof.
  • The Triad Of Health System provides for an infinite number of therapies to choose from.
  • This unique system of checks and balances is light years ahead of any other therapeutic modality currently available.
  • Follow this link to register for and learn more about The Seven Pitfalls You Must Avoid To Heal Your Auto-Immune Thyroid event:
    Triad Of Health Family Healing Center is located in Northern California at 4340 Redwood Highway, Suite D318, San Rafael, CA 94903.